1.0UShttps://organonpro.com/en-usjasonmeihttps://organonpro.com/en-us/author/jasonmei/Coveragerich600338<blockquote class="wp-embedded-content" data-secret="vO0iqcNSZe"><a href="https://organonpro.com/en-us/product/renflexis/coverage/">Coverage</a></blockquote><iframe sandbox="allow-scripts" security="restricted" src="https://organonpro.com/en-us/product/renflexis/coverage/embed/#?secret=vO0iqcNSZe" width="600" height="338" title="“Coverage” — US" data-secret="vO0iqcNSZe" frameborder="0" marginwidth="0" marginheight="0" scrolling="no" class="wp-embedded-content"></iframe><script>
/*! This file is auto-generated */
!function(d,l){"use strict";l.querySelector&&d.addEventListener&&"undefined"!=typeof URL&&(d.wp=d.wp||{},d.wp.receiveEmbedMessage||(d.wp.receiveEmbedMessage=function(e){var t=e.data;if((t||t.secret||t.message||t.value)&&!/[^a-zA-Z0-9]/.test(t.secret)){for(var s,r,n,a=l.querySelectorAll('iframe[data-secret="'+t.secret+'"]'),o=l.querySelectorAll('blockquote[data-secret="'+t.secret+'"]'),c=new RegExp("^https?:$","i"),i=0;i<o.length;i++)o[i].style.display="none";for(i=0;i<a.length;i++)s=a[i],e.source===s.contentWindow&&(s.removeAttribute("style"),"height"===t.message?(1e3<(r=parseInt(t.value,10))?r=1e3:~~r<200&&(r=200),s.height=r):"link"===t.message&&(r=new URL(s.getAttribute("src")),n=new URL(t.value),c.test(n.protocol))&&n.host===r.host&&l.activeElement===s&&(d.top.location.href=t.value))}},d.addEventListener("message",d.wp.receiveEmbedMessage,!1),l.addEventListener("DOMContentLoaded",function(){for(var e,t,s=l.querySelectorAll("iframe.wp-embedded-content"),r=0;r<s.length;r++)(t=(e=s[r]).getAttribute("data-secret"))||(t=Math.random().toString(36).substring(2,12),e.src+="#?secret="+t,e.setAttribute("data-secret",t)),e.contentWindow.postMessage({message:"ready",secret:t},"*")},!1)))}(window,document);
//# sourceURL=https://organonpro.com/en-us/wp-includes/js/wp-embed.min.js
</script>
RENFLEXIS is an FDA-approved biosimilar of REMICADE (infliximab) based on data demonstrating that it is highly similar and that there are no clinically meaningful differences in safety and effectiveness between the two infliximab products. RENFLEXIS Product Access Coverage and reimbursement support The Organon Access Program for RENFLEXIS can help answer questions about insurance coverage for patients; benefits investigations; […]https://organonpro.com/en-us/wp-content/uploads/sites/6/2022/12/organon-pro-og-img.png1200630